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Background: This study aims to evaluate the efficacy of Black cohosh (Cimicifuga racemosa L.) in treating early
menopausal symptoms.
Methods: This randomized, double-blind, placebo-controlled clinical trial was conducted on 84 early post-menopausal
participants with Greene climacteric scale (GCS) scores of 15 to 42, who were referred to two public health care centers
in Tehran, Iran, in 2011–2012. The participants were randomly allocated into treatment (6.5 mg of dried extract of Black
cohosh roots daily) and control (placebo) groups with a ratio of 1:1. The participants took one tablet per day for 8 weeks.
The GCS scores were recorded at baseline, and after 4 and 8 weeks of treatment. Data analysis was carried out using a
general linear model with repeated measures with SPSS software. The level of significance was set at P < 0.05.
Results: There was no loss to follow-up during the 8 weeks of treatment. The GCS total score (primary outcome)
in the treatment group was significantly lower than that in the control group at both week 4 [adjusted mean
difference: −7.8 (95% confidence interval: −11.1 to −4.4)] and week 8 [−12.9 (−16.2 to −9.3)]. The treatment group
showed significantly more improvement than the control group in all GCS subscale scores (vasomotor, psychiatric,
physical, and sexual symptoms; secondary outcomes). The differences between the treatment and control groups at
week 8 were significantly higher (P < 0.001) than those at week 4 in terms of the total scores and the vasomotor and
psychiatric subscale scores. No side effects were reported.
Conclusions: Black cohosh reduced the GCS total score and all GCS subscale scores (vasomotor, psychiatric, physical,
and sexual symptoms) during 4 and 8 weeks of treatment.
Clinical trial registration: This study was approved (Code 9061) by the Ethics Committee of Tabriz University of
Medical Sciences and registered at the Iranian Registry of Clinical Trials with IRCT201107186709N4 on 15 January 2012.Background
Menopause is the final menstrual period, and occurs
at an average age of 51 years [1,2]. The number of
peri-menopausal women is increasing in the world [1].
Menopause happens because of loss of ovarian activ-
ity, and is associated with a number of early and late
symptoms. Early symptoms include hot flashes, insomnia,
sweating, anxiety, palpitations, headaches, poor concentra-
tion, and loss of libido [3,4]. These symptoms usually last
for 1 or 2 years after menopause, but may continue up to
10 years or more in some women [2]. The symptoms may
reduce quality of life, and are independent of age and* Correspondence: jnahaee@yahoo.com
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unrestricted use, distribution, and reproductioother sociodemographic variables [5]. In a study in Ilam,
Iran, early post-menopausal women suffered vasomotor
symptoms (55%), vaginal dryness and decreased libido
(43%), and mild anxiety and depression (54%) [6].
Hormone replacement therapy is the standard treatment
for early symptoms in post-menopausal women [7], but
increases the risks of stroke, heart diseases, and breast
cancer in older women [8,9]. Some studies have shown that
the number of post-menopausal women using hormone
replacement therapy is low [10] and that the effects of
hormone replacement therapy in reducing menopausal
symptoms are lower than expected [11,12]. For these
reasons, there has been a tendency toward use of alterna-
tive therapies to relieve menopausal symptoms [13,14].l.; licensee BioMed Central Ltd. This is an open access article distributed under
n License (http://creativecommons.org/licenses/by/2.0), which permits
n in any medium, provided the original work is properly cited.
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http://www.cmjournal.org/content/8/1/20Black cohosh (Cimicifuga racemosa L.) is an herb
proposed for treatment of menopausal symptoms [15].
Cimicifuga roots and rhizomes contain triterpene gly-
cosides (e.g., actein, 27-deoxyactein, and cimifugaside) and
alkaloids (e.g., cytisine and N-methyl cytisine), derivatives
of phenylpropane (e.g., ferulic acids and isoferulic acids),
and cimicifugine (25–50% of the root components) [15].
Although the exact mechanisms underlying the effects
of Black cohosh have not been determined, its medical
effects are related to triterpene glycosides [16]. It functions
in a serotogenic manner rather than an estrogenic manner
[17-19], binds to estrogen receptors, and selectively sup-
presses luteinizing hormone secretion with no effect on
follicle-stimulating hormone [20].
The effects of Black cohosh on early menopausal symp-
toms have been inconsistent [21-25]. A systematic review
[26] conducted on six randomized controlled trials (RCTs)
with a total of 1163 peri- and post-menopausal women
concluded that the efficacy of Black cohosh in reducing
the symptoms was currently not supported by fully con-
clusive evidence, and that further investigations were de-
sirable. Another review [27] of 16 studies that addressed
the weaknesses of previous studies and their heterogeneity
found insufficient evidence to support the efficacy of Black
cohosh on early menopausal symptoms.
Black cohosh is well tolerated and is generally safe
[15,26,28,29]. However, some insignificant side effects,
such as nausea, vomiting, headaches, and dizziness were
reported [15,26]. We found no data for toxic doses of
Black cohosh. No serious side-event was reported even
in a study [24] using a higher dose of Black cohosh that
included 128 mg/day standardized to 7.27 mg of triter-
pene glycosides (ethanolic extract of Black cohosh).
The Greene climacteric scale (GCS), which is used to
assess the symptoms of menopause, is a comprehensive
validated tool consisting of 21 questions that women use
to rate how much they are bothered by the symptoms [30].
The inconclusive evidence on the efficacy of Black co-
hosh has resulted in inconsistent practices by clinicians
regarding the prescription of Black cohosh in the study
area, leading to confusion for some patients on their de-
cision about its use. To provide more evidence in this
area, this study aims to evaluate the efficacy of Black co-
hosh on early menopausal symptoms using an RCT.
Methods
Design
This study was a randomized, double-blind, placebo-
controlled trial. A total of 84 menopausal women were
randomly allocated into treatment and control groups
based on a block randomization with block sizes of 4
and 6 and an allocation ratio of 1:1. The allocation se-
quence was identified by computerized random numbers.
Sequentially numbered sealed envelopes of the same shapeand size containing Black cohosh or placebo tablets were
used to conceal the allocation and to maintain the
blinding. Every envelope contained 56 pills of Black co-
hosh or placebo. The participants were instructed to
take one tablet per day after dinner for 8 weeks.
The envelopes were prepared by a person who was not
involved in the recruitment, data collection, or data ana-
lysis. Therefore, the researchers and participants were
unaware of the kind of tablets given to each participant
(blinding).
The Black cohosh tablets, which were bought from a
pharmacy, were in the form of coated tablets. Each tablet
contained 6.5 mg of dried extract of Black cohosh root,
representing 0.12–0.18 mg of 27-deoxyactein. The tablets,
named Cimifugol, are commercially distributed by
Goldaroo Drug Company in Iran [31]. The placebo
tablets were produced in the School of Pharmacy of
Tabriz University of Medical Sciences. These tablets
were the same as the Black cohosh tablets in shape,
color, and size, and were thus indistinguishable from
the Black cohosh tablets.
Setting and participants
Women who met the following criteria were eligible for
recruitment: (1) age of 45–60 years; (2) no menstrual
cycle in the last 12 months; and (3) GCS score of 15–42.
The exclusion criteria included: (1) high blood pressure
(more than 140/90 mmHg); (2) history of breast cancer,
uterine cancer, abnormal vaginal bleeding, liver disease,
depression, hypertension, or hyperthyroidism; (3) use of
steroids or herbal medications for treatment of menopausal
symptoms or psychiatric drugs within the last 2 months;
(4) sensitivity to spices or essences; (5) smoking; and
(6) alcohol consumption.
The subjects were selected from women referred to
two public health care centers affiliated to Beheshti Uni-
versity of Medical Sciences, Tehran, Iran. These centers
had the highest numbers of clients for family planning
services among the centers affiliated to the university.
All participants had household records at the centers for
receipt of primary health care, including family planning
services, in previous years and had reached the age of
menopause. To contact the participants, we found their
phone numbers from the records. Some of the eligibility
criteria were checked over the phone. The potentially
eligible subjects were invited to attend the centers. At
the centers, the women were further informed about the
study, the eligibility criteria were checked precisely, and
informed consent forms were signed by the eligible women.
The research protocol were approved (Code 9061) by
the Ethics Committee of Tabriz University of Medical
Sciences and registered at the Iranian Registry of Clinical
Trials with IRCT201107186709N4 on 15 January 2012
(http://www.irct.ir/searchresult.php?id=6709&number=4).
Table 1 Demographic characteristics of the study participants in the treatment (Black cohosh) and control
(placebo) groups
Variables Treatment Control Statistical results
(n = 42) (n = 42)
Mean ± SD Mean ± SD
Age (years) 51.4 ± 4 51.7 ± 4.2 t = 0.78, df = 82, P = 0.43
Length of menopause (months) 35.1 ± 20.6 31.4 ± 21.3 t = 0.82, df = 82, P = 0.41
Systolic blood pressure (mmHg) 115.7 ± 13.5 115.2 ± 8.6 t = 0.19, df = 82, P = 0.84
Diastolic blood pressure (mmHg) 79.2 ± 6.7 77.3 ± 6.6 t = 1.30, df = 82, P = 0.19
Body mass index (kg/m2) 27.6 ± 3.6 26.3 ± 2.9 t = 1.83, df = 82, P = 0.07
n (%) n (%)
Education
Elementary 9 (21) 6 (14) χ2 = 4.49
Secondary 4 (9) 11 (26) df = 3
High school 20 (47) 19 (45) P = 0.21
Academic 9 (21) 6 (14)
Employment
Housewife 33 (78) 33 (78) χ2 = 0.22
Employed 4 (9) 5 (11) df = 2
Retired 5 (11) 4 (9) P = 0.89
Income adequacy
Yes 15 (35) 14 (33) χ2 = 0.17
To some extent 24 (57) 24 (57) df = 2
No 3 (7) 4 (9) P = 0.91
Exercise
Never 7 (17) 10 (24) χ2 = 0.71
Sometimes 15 (36) 13 (31) df = 3
Often 13 (31) 12 (28) P = 0.87
Always 7 (17) 7 (17)
Marital status
Married 40 (95) 36 (86) χ2 = 3.54
Single 1 (2) 2 (4) df = 3
Divorced 1 (2) 1 (2) P = 0.31
Widowed 0 (0) 3 (3)
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version 9.2 (Statasoft Inc., USA) based on a study by
Hakimi et al. [32]. Considering 28.1 as the mean and
1.98 as the standard deviation for the GCS score in the
control group, a reduction in the GCS total score of at
least 15% by the treatment, a one-sided significance level
of 0.05, a power of 0.80, and a 10% probable drop in the
sample, the required sample size was calculated to be 42
participants per group.
Outcomes
The primary outcome was the GCS total score assessed
at weeks 4 and 8 of follow-up and the secondary outcomeswere the GCS subscale scores (vasomotor, physical, psy-
chiatric, and sexual symptoms) at the follow-ups as well as
also possible side effects.
Data collection
Data were collected at baseline prior to the treatment,
and also at weeks 4 and 8 after commencement of the
treatment using a questionnaire. The questionnaire in-
cluded demographic and GCS statements [30], which were
completed in face-to-face interviews by the participants at
the visits. The participants were also given a form, and
were requested to mark their taking of the pills and the
occurrence of any side effects (e.g., headaches, dizziness,
Table 2 Comparisons of the treatment (Black cohosh) and control (placebo) groups in terms of the Greene climacteric
scale total and subscale scores at baseline and two follow-up time-points
Outcome variables Treatment
(n = 42) Mean ± SD
Control
(n = 42) Mean ± SD
Comparison of the groups
Adjusted MD (95% CI) P Partial Eta2
Total score (0–63)
Baseline 33.8 ± 6.4 31.1 ± 6.3 2.7 (−0.1 to 5.4) 0.059
4 weeks 16.7 ± 7.7 22.9 ± 9.2 −7.8 (−11.1 to −4.4) < 0.001 0.21
8 weeks 8.0 ± 5.5 19.5 ± 11.0 −12.9 (−16.2 to −9.3) < 0.001 0.39
Vasomotor symptoms (0–6)
Baseline 4.0 ± 1.7 3.5 ± 1.6 0.5 (−2.9 to 1.2) 0.22
4 weeks 1.8 ± 2.0 2.6 ± 1.7 −1.1 (−0.4 to −1.8) 0.002 0.11
8 weeks 0.7 ± 1.6 2.4 ± 1.8 −1.9 (−1.2 to −2.6) < 0.001 0.26
Psychiatric symptoms (0–33)
Baseline 18.8 ± 4.8 18.8 ± 4.3 0.1 (−2.1 to 1.9) 0.92
4 weeks 10.8 ± 5.0 13.3 ± 6.4 −2.6 (−0.3 to −4.9) < 0.001 0.16
8 weeks 4.2 ± 3.5 11.4 ± 7.4 −7.3 (−9.6 to −5.0) < 0.001 0.31
Physical symptoms (0–21)
Baseline 7.7 ± 3.5 6.6 ± 2.7 1.1 (−0.3 to 2,5) 0.10
4 weeks 3.1 ± 2.3 4.7 ± 2.8 −2.0 (−3.1 to −1.0) < 0.001 0.06
8 weeks 1.4 ± 1.5 3.7 ± 2.4 −2.5 (−3.3 to −1.7) < 0.001 0.33
Loss of interest in sex (0–3)
Baseline 2.6 ± 0.8 2.4 ± 1.4 0.2 (−0.7 to 0.3) 0.47
4 weeks 1.8 ± 1.0 1.9 ± 1.0 −0.37 (−0.72 to −0.03) 0.03 0.06
8 weeks 1.6 ± 1.1 1.9 ± 1.0 −0.52 (−0.89 to −0.15) 0.006 0.09
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it to the researcher at the next visit. Furthermore, we
checked the treatment compliance and possible side
effects over the phone once a week.
The GCS scale consisted of 21 statements. Eleven state-
ments pertained to psychiatric symptoms, and included
two parts, anxiety and depression. Seven statements
assessed physical aspects and two assessed vasomotor
symptoms. The final statement considered sexual desire
disorder. The severity of the symptoms was scored as
zero (no symptoms), one (mild), two (moderate), and three
(severe) based on self-reporting [30]. To determine the
reliability, a test-retest was used (r = 0.96).
Statistical analysis
The normality of the quantitative variables for each of the
groups was confirmed using the Kolmogorov-Smirnov
test. An independent t-test was used for comparison of
the baseline scores, and a general linear model with
repeated measures was used for comparison of the follow-
up scores adjusted for the baseline values, time, and inter-
action between time and group. The Greenhouse-Geisser
test was used to determine the interaction effect. A partial
Eta2 value was recorded for the effect size of the treatment
and the interaction. All data analyses were carried outusing SPSS for Windows 13.0 (SPSS Inc., USA). Values of
P < 0.05 were considered to indicate statistical significance.
Results
There was no loss to follow-up and all participants con-
tinued the study to the end. Both groups were similar in
terms of the personal and societal characteristics (Table 1).
The average age in both groups was approximately
51 years. The majority of patients in both groups had
high school education or above, and were married
housewives. Overall, 17% of women in the treatment
group and 24% in the control group did no exercise at all.
At baseline, the mean ± standard deviation of the GCS
total score was 33.8 ± 6.4 in the treatment group and
31.1 ± 6.4 in the control group, with no significant dif-
ference. In addition, the groups had similar scores for
all GCS subscales (Table 2).
The GCS total score in the treatment group was sig-
nificantly lower than that in the control group at both
week 4 [adjusted mean difference: −7.8 (95% confidence
interval: −11.1 to −4.4), P < 0.001] and week 8 [−12.9
(−16.2 to −9.3), P < 0.001]. The treatment group also
showed significantly more improvement than the control
group in all GCS subscale scores (vasomotor, psychiatric,














Figure 1 Trend in the Greene climacteric scale total score and subscale scores at the two follow-up time points (*results of the
Greenhouse-Geisser test in the general linear model with repeated measures for the interaction between time and group; ES: effect
size based on the partial Eta2).
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in the GCS total score (relative effect) in the treatment
group compared with 27% and 38% in the control group,
respectively. Reductions in the vasomotor symptom
score of 61% and 86% were observed in the treatment
group compared with 27% and 29% in the control group.
The reductions in the psychiatric symptom score were
46% and 79% in the treatment group compared with
31% and 42% in the control group. The reductions in
the physical symptom score were 63% and 82% in the
treatment group compared with 27% and 42% in the
control group. The reduction in the loss of interest in
sex score were 29% and 36% in the treatment group
compared with 8% and 10% in the control group. The
effect size was considerable (partial Eta2: > 0.3) in terms
of the total, physical, and psychiatric symptoms at 8 weeks
of follow-up (Table 2).
The differences between the treatment and control
groups at week 8 were significantly higher than those at
week 4 in terms of the total score (P < 0.001) and vaso-
motor (P = 0.001) and psychiatric (P < 0.001) subscale
scores. In the other two subscales, physical and sexual
symptoms, the effects were higher at week 8, but the
differences were not significant compared with week 4(P = 0.199 and P = 0.237, respectively) (Figure 1). No
side effects were reported in either of the groups.
Discussion
Intake of Black cohosh (6.5 mg of dried extract of the
roots of the plant) for 8 weeks, comprising one tablet
every night after dinner, reduced the symptoms in early
post-menopausal women compared with intake of placebo.
The treatment efficacy increased with longer use.
The results of this study are consistent with the results
of some previous studies comparing the effects of daily
intake of 6.5 mg of dried rhizome extract of Black cohosh
[21] or 40 mg of herbal drug Black cohosh with peri- and
post-menopausal women [22,23] on reducing climacteric
complaints compared with intake of placebo, and the
women in the early climacteric phase benefited more
than those in the late phase [22].
The effects of Black cohosh on reducing climacteric
symptoms in peri- and post-menopausal women were
similar to those of other effective treatment methods like
conjugated estrogens [23] and tibolone [33], and even
higher than those of fluoxetine [34].
The present results appear inconsistent with the results
of some other studies. Geller et al. [24] showed that the
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number of vasomotor symptoms was not significantly
different from that of placebo and was significantly lower
than 0.625 mg of conjugated equine estrogens plus 2.5 mg
medroxyprogesterone acetate. The difference may be
related to the longer interval between the initiation of
treatment and the outcome assessment, since the study
outcome was assessed at 12 months after initiation of
the treatment compared with 2 months in our study.
Jacobson et al. [35] demonstrated that Black cohosh
was not significantly effective in reducing most post-
menopausal symptoms. However, all participants in their
study had breast cancer and most (70%) were taking
tamoxifen. Higher loss of follow-up (20%) may also have
affected the results. Amsterdam et al. [25] demonstrated
that Black cohosh did not significantly reduce the GCS
scores in peri- and post-menopausal women. This in-
consistency with our results may be related to the small
sample size (only 28), relatively higher loss to follow-up
(25%), or choice of Black cohosh preparation and dos-
age. No adverse side effects were seen in our Black
cohosh users, consistent with the results of other studies
[22,23,25,33,34].
The double-blinding and no loss to follow-up were
important strengths of this study. The duration of the
treatment in this study was relatively short (8 weeks)
and we did not have any follow-up after ceasing Black
cohosh use because of time and financial limitations.
Although the GCS score is a subjective outcome (self-
reporting), the results may not be affected by subjectivity
because of the double blinding of the study. Other
outcomes like urogenital and ophthalmic symptoms,
follicle-stimulating hormone serum levels, and bone
metabolism were not assessed, and safety was only
assessed by self-reporting because of financial limitations.
In addition, the effect of Black cohosh was not compared
with a standard treatment, i.e., hormone replacement ther-
apy based on the results.
Conclusions
Black cohosh reduced the GCS total score and all GCS
subscale scores (vasomotor, psychiatric, physical, and sexual
symptoms) during 4 and 8 weeks of treatment.
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